Enzon Pharmaceuticals, Inc.
ENZN
$0.0998
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00% | 0.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00% | 0.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00% | 0.00% | -- | -- |
| SG&A Expenses | 29.60% | 16.81% | 5.37% | 3.73% | -1.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.60% | 16.81% | 5.37% | 3.73% | -1.32% |
| Operating Income | -27.11% | -17.23% | -5.51% | -6.37% | -1.16% |
| Income Before Tax | -7.56% | 42.84% | 173.80% | 1,838.03% | 415.28% |
| Income Tax Expenses | 322.44% | -85.71% | 6.15% | 48.05% | 22.00% |
| Earnings from Continuing Operations | -43.34% | 47.20% | 127.65% | 395.36% | 838.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.34% | 47.20% | 127.65% | 395.36% | 838.17% |
| EBIT | -27.11% | -17.23% | -5.51% | -6.37% | -1.16% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -607.69% | 206.25% | 155.13% | 122.90% | 106.60% |
| Normalized Basic EPS | -6.80% | 44.87% | 172.73% | 1,833.33% | 412.12% |
| EPS Diluted | -842.86% | 143.75% | 122.12% | 106.37% | 96.86% |
| Normalized Diluted EPS | -6.80% | 44.87% | 172.73% | 1,833.33% | 412.12% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.76% | -0.32% | -0.56% | -0.80% | -- |